Expertise in
10
conditions

Dr. Joel R. Hecht

Oncology
The Regents Of The University Of California
200 Medical Plz, 
Los Angeles, CA 
Offers Telehealth
Expertise in
10
conditions
The Regents Of The University Of California
200 Medical Plz, 
Los Angeles, CA 

Overview

Joel Hecht is an Oncologist practicing medicine in Los Angeles, California.

Dr. Hecht is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Neuroendocrine Tumor, and Familial Pancreatic Cancer.

He is actively involved in clinical research, co-authoring 13 peer reviewed articles and participating in 8 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

Ronald Reagan UCLA Medical Center
Santa Monica - UCLA Med Ctr & Orthopaedic Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

The Regents of the University of California
200 Medical Plz, Los Angeles, CA 90095

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Study Phase: Phase 1
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer
Enrollment Status: Terminated
Publish Date: January 24, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer
A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer
Enrollment Status: Completed
Publish Date: March 01, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
An Open Label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Progressing After First-Line Therapy
An Open Label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Progressing After First-Line Therapy
Enrollment Status: Terminated
Publish Date: March 26, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-label, Multicenter, Phase 2 Trial Investigating Sym004 in Patients With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies and Documented Mutation of Extra Cellular Domain of EGFR (ECD-EGFR)
An Open-label, Multicenter, Phase 2 Trial Investigating Sym004 in Patients With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies and Documented Mutation of Extra Cellular Domain of EGFR (ECD-EGFR)
Enrollment Status: Withdrawn
Publish Date: February 01, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

13 Total Publications

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.
Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: September 02, 2026
Similar Doctors
Expertise in
40
conditions
Expertise in
40
conditions
Referral may be required

UCLA Health Bowyer Oncology Center

200 UCLA Medical Plz Ste 120, 
Los Angeles, CA 
 (0.5 miles away)
310-206-6745
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gary Schiller is an Oncologist practicing medicine in Los Angeles, California. Dr. Schiller is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), and Bone Marrow Aspiration.

Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required

Office

200 Medical Plz, 
Los Angeles, CA 
 (0.1 miles away)
310-206-6909
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Zev Wainberg is an Oncologist practicing medicine in Los Angeles, California. Dr. Wainberg is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Gastroesophageal Junction Cancer, Pancreatic Cancer, Stomach Cancer, Pancreaticoduodenectomy, and Tissue Biopsy.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

The Regents Of The University Of California

200 Medical Plz, 
Los Angeles, CA 
 (0.1 miles away)
310-206-6931
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Edward Garon is an Oncologist practicing medicine in Los Angeles, California. Dr. Garon is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

Frequently Asked Questions about Dr. Joel R. Hecht

How do I make an appointment with Dr. Joel R. Hecht?

You can book an appointment with Dr. Joel R. Hecht by calling their office at 310-586-2097. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joel R. Hecht a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joel R. Hecht is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joel R. Hecht specialize in?

While Dr. Joel R. Hecht is a Oncology, they have specific expertise in Colorectal Cancer, Familial Colorectal Cancer, and Neuroendocrine Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Joel R. Hecht participate in research or clinical trials?

Yes. Dr. Joel R. Hecht has published 13 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Joel R. Hecht's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joel R. Hecht accept my insurance?

Dr. Joel R. Hecht accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 310-586-2097 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hecht's expertise for a condition
ConditionClose
    View All 34 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile